A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

Status unconfirmed · Phase 2

Conditions studied: Multiple Sclerosis

In brief

This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.

Key facts

Study ID

NCT00217295

Run by

Multiple Sclerosis Institute

People needed

30

Starts

2004-04-01

Expected to finish

2007-12-01

Last updated by the study team

2005-09-22

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsing-remitting multiple sclerosis

You may not qualify if…

• Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -

Where it is running

• Multiple Sclerosis Institute — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.